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Abstract
Background: There is limited data on complications associated with the use of
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coronary embolic protection devices (EPDs).
Methods: We queried the Manufacturer and User Facility Device Experience database
between November 2010 and November 2020 for reports on coronary EPDs: Spider
FX (Medtronic, Minneapolis, MN) and Filterwire EZ (Boston Scientific, Natick, MA).
Results: We retrieved 119 reports on coronary EPD failure (Spider FX n = 33 and
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Filterwire EZ n = 86), most of which (78.2%) occurred during saphenous vein graft
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(49.6%), with the filter trapped against stent struts in 76.2% of the cases. Other

5

interventions. The most common failure mode was inability to retrieve the EPD
device complications included filter fracture (28.6%), failure to cross (7.6%), failure to
deploy (7.6%), and failure to recapture the filter (3.4%). Filter fracture (54.5
vs. 29.1%) and failure to recapture (9.1 vs. 2.1%) were more commonly reported,
while failure to deploy the filter (0 vs. 10.5%) was less commonly reported with the
Spider-FX.
Conclusions: The most common modes of failure of coronary EPDs are the failure of
retrieval (49.6%), followed by the filter fracture (28.6%). When using EPDs, careful
attention to the technique is essential to avoid failures and subsequent complications.
KEYWORDS
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I N T RO DU CT I O N

Embolic protection devices (EPDs) can prevent or reduce the
extent of distal embolization of debris or thrombus, potentially reducing

Distal embolization is a potential risk of percutaneous coronary

adverse clinical outcomes. Randomized trials have shown beneficial effects

intervention (PCI) that can lead to slow or no-reflow and acute vessel

of EPDs on SVG interventions.3 EPDs have demonstrated no significant

1,2

Emboli-

benefit when routinely used in STEMI,4,5 although some reports suggest

zation can occur at the time of lesion crossing, balloon inflation, or

benefit, for example, in patients with attenuated plaque.6,7 Currently,

stent deployment. Distal embolization is most pronounced in lesions

EPDs are primarily used in SVG PCI.8 Data on the complications of coro-

with a high plaque or thrombus burden, such as ST-segment elevation

nary EPDs are limited.9 Therefore, we examined the reports of coronary

acute myocardial infarction (STEMI) culprit lesions and saphenous vein

EPDs failure reported to the Food and Drug Administration (FDA) Manu-

graft (SVG) lesions.3

facturer and User Facility Device Experience (MAUDE) registry.

closure, potentially leading to acute myocardial infarction.

Catheter Cardiovasc Interv. 2021;1–6.
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TABLE 1

Reports of the Spider FX and Filterwire EZ device failure in the MAUDE registry
Overall (n = 119)

SPIDER-FX (n = 33)

FILTERWIRE-EZ (n = 86)

p-value

Saphenous vein graft, n (%)

93 (78.2)

24 (72.2)

69 (80.2)

.37

Native, n (%)

14 (11.8)

6 (18.2)

8 (9.3)

.40

RCA, n (%)

9 (7.6)

5 (15.2)

4 (4.7)

.05

LAD, n (%)

3 (2.5)

1 (3)

2 (2.3)

.82

LCX, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

Coronary location

OM, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

Unknown, n (%)

12 (10)

3 (9.1)

9 (10.5)

.82

Failure of retrieval, n (%)

59 (49.6)

19 (57.6)

40 (46.5)

.28

Trapped against stent struts (total n = 59) (%)

45 (76.2)

8 (42.1)

20 (50.0)

.57

Modes of failure

Filter fracture, n (%)

34 (28.6)

18 (54.5)

25 (29.1)

.01

Failure of crossing, n (%)

13 (7.6)

2 (6.1)

11 (12.8)

.29

Failure of deployment, n (%)

9 (7.6)

0 (0)

9 (10.5)

.05

Failure of recapturing, n (%)

4 (3.4)

3 (9.1)

1 (1.2)

.03

67 (56.3)

8 (24.2)

59 (68.6)

Management
Successful catheter-based retrieval, n (%)

<.001

Snare, n (%)

12 (10.1)

5 (15.2)

7 (8.1)

.25

Rotational atherectomy to dislodge trapped filter, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

Guide extension catheter, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

Left inside patient, n (%)

38 (31.9)

18 (54.5)

20 (23.3)

<.001

Filter jailed with a stent, (total n = 38) (%)

20 (52.6)

9 (50.0)

11 (55.0)

.75

Surgical retrieval, n (%)

13 (10.9)

7 (21.2)

6 (7)

.02

Stent deformation during retrieval, n (%)

34 (28.6)

4 (3.4)

30 (34.9)

.01

No reflow, n (%)

7 (5.9)

3 (9.1)

4 (4.7)

.35

Complications

Slow flow, n (%)

11 (9.2)

5 (15.2)

6 (7.1)

.17

Acute stent thrombosis, n (%)

1 (0.8)

1 (3)

0 (0)

.10

Coronary perforation, n (%)

2 (1.7)

0 (0)

2 (2.3)

.37

Coronary artery dissection, n (%)

3 (2.5)

1 (3)

2 (2.3)

.82

Hemodynamic collapse, n (%)

2 (1.7)

2 (6.1)

0 (0)

.02

Respiratory arrest, n (%)

2 (1.7)

1 (3)

1 (1.2)

.47

Embolized

13 (10.9)

5 (15.2)

8 (9.3)

.60

Microthrombi embolization, n (%)

4 (3.4)

1 (20)

3 (37.5)

.50

Femoral embolization, n (%)

2 (1.7)

1 (20)

1 (12.5)

.71

Abdominal embolization, n (%)

1 (0.8)

1 (20)

0 (0)

.18

Iliac embolization, n (%)

1 (0.8)

0 (0)

1 (12.5)

.41

Brachial embolization, n (%)

1 (0.8)

1 (20)

0 (0)

.18

Periprocedural MI, n (%)

10 (8.4)

2 (6.1)

8 (9.3)

.56

Stroke, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

Death, n (%)

1 (0.8)

0 (0)

1 (1.2)

.53

103 (86.6)

27 (81.8)

76 (88.4)

.34

Outcome
Successful intervention completed, n (%)

Abbreviations: LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; OM, obtuse marginal artery; SVG, saphenous
vein grafts.
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F I G U R E 1 Modes of failures of coronary
embolic protection devices as reported to the
MAUDE registry. MAUDE, Manufacturer and User
Facility Device Experience

2

MATERIALS AND METHODS

|
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Results

The FDA's MAUDE database is an online database of adverse events

A total of 677 reports were found during the study period. After exclud-

caused by an approved medical device. Reporting to the MAUDE

ing non-coronary (n = 455) and non-identifiable lesions (n = 113), our

database is either mandatory (for manufacturers and device user

final cohort included 119 reports related to EPD failure during PCI. Of

facilities) or voluntary (for healthcare professionals, patients, and

those, 33 reports were related to the use of the Spider FX (27.7%) and

consumers). We searched the database from November 2010

86 to the Filterwire EZ (72.3%) (Figure S1). Most reports were during

to November 2020 for reports on coronary EPDs: Spider FX

SVG PCI (78.2%), while native coronary artery PCI was 11.8%. We could

(Medtronic, MN) and Filterwire EZ (Boston Scientific, MA). The

not identify the target vessel in 10% of cases (Table 1).

Spider FX device was the most recently approved in 2011. The
Guardwire (Medtronic, Minneapolis, MN) and Proxis devices,
although FDA approved, were omitted because they are not cur-

2.3

|

Mechanisms of failure and clinical outcomes

rently commercially available in the US.
The database was last accessed on December 15, 2020, by

The most common failure mode was failure to retrieve the EPD

two independent reviewers (RM and MM). The MAUDE data-

(49.6%), with the filter trapped against stent struts in 76.2% of

base is publicly available and de-identified; therefore, no institu-

these cases. Other EPD complications included filter fracture

tional review board approval was required for this study. We

(28.6%), failure to cross (7.6%), failure to deploy (7.6%), and fail-

compared the baseline characteristics and outcomes between

ure to recapture the filter (3.4%). There was no difference in the

the Spider-FX and Filterwire-EZ. We also compared outcomes in

incidence of failure of retrieval or crossing between the two fil-

patients who had EPDs used in SVGs versus in native coronary

ters. Spider-FX had higher reported incidence of filter fracture

disease.

(54.5% vs. 29.1%, p = .01) and failure to recapture (9.1 vs. 2.1%,
p = .03), but lower reported incidence of filter deployment failure (0 vs. 10.5%, p = .05) compared with the Filterwire-EZ

2.1

|

Outcomes and statistical analysis

(Figure 1).
Management of entrapment was with catheter-based retrieval in

The primary outcome of this study was the mechanisms of

57.1% of the cases, while surgical retrieval was needed in 10.9% of

failure of coronary EPDs. Secondary outcomes included clinical

the reports. Successful catheter-based retrieval was reported in

consequences of device failure. Failure of retrieval of the EPD

66.3% of the Filterwire-EZ reports, and 34.4% of the Spider FX

was defined as the failure to extract the filter intact from the

reports. Surgical intervention was reported in 21% of the Spider-FX

vessel. Failure of recapture was defined as the inability to with-

cases and 7% of the Filterwire-EZ cases. The device was left in place

draw the filter in the retrieval catheter. Categorical variables

in 31.9% of the cases, and jailed by a stent in 52.6% of them. The Spi-

were described as numbers and percentages. They were ana-

der FX was left in place in 54.5% of the reports compared with 23.3%

lyzed using Pearson's chi-square or Fisher's exact tests. A value

for the Filterwire-EZ.

of p < .05 was considered significant, and p-values are two-

Stent deformation occurred in 28.6% of the reports, with a higher

sided where possible. All statistical calculations were performed

incidence with the Filterwire-EZ (34.9 vs. 3.4%, p = .01). Device

with IBM SPSS Statistics for Mac, Version 26.0. Armonk, NY:

embolization occurred in 10.9% of cases with no difference between

IBM Corp (2020).

both devices. The rates of slow flow and no-reflow were 9.2 and

4
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T A B L E 2 Subgroup analysis of clinical complication of embolic protection devices in native coronary artery versus vein graft interventions in
the MAUDE registry
Overall (n = 107)

Native coronary arteries (n = 14)

Vein grafts (n = 93)

p-value

53 (49.5)

3 (21.4)

50 (53.8)

.24

Trapped against stent struts (total n = 59) (%)

45 (42.1)

5 (35.7)

40 (43.0)

.60

Filter fracture, n (%)

40 (37.4)

5 (35.7)

35 (37.6)

.89

Failure of crossing, n (%)

12 (11.2)

1 (7.1)

11 (11.8)

.60

Failure of deployment, n (%)

7 (6.5)

0 (0)

7 (7.5)

.28

Failure of recapturing, n (%)

3 (2.9)

2 (14.3)

1 (1.1)

<.001

Successful catheter-based retrieval, n (%)

60 (56.1)

8 (57.1)

52 (55.9)

.93

Snare, n (%)

12 (11.2)

0 (0)

12 (12.9)

.15

Rotational atherectomy to dislodge trapped filter, n (%)

1 (0.9)

1(7.1)

0 (0)

.01

Guide extension catheter, n (%)

1 (0.9)

1 (7.1)

0 (0)

.01

Left inside patient, n (%)

35 (32.7)

4 (28.6)

31 (33.3)

.72

Filter jailed with a stent, (total n = 35) (%)

20 (52.6)

2 (50.0)

17 (54.8)

.71

Surgical retrieval, n (%)

11 (10.3)

2 (14.3)

9 (9.7)

.59

Stent deformation during retrieval, n (%)

33 (30.8)

4 (28.6)

29 (31.2)

.84

No reflow, n (%)

7 (6.5)

0 (0)

7 (7.5)

.28

Mode of failure
Failure of retrieval, n (%)

Management

Complications

Slow flow, n (%)

11 (10.4)

0 (0)

11 (12)

.17

Acute stent thrombosis, n (%)

1 (0.9)

1 (7.1)

0 (0)

.10

Coronary perforation, n (%)

2 (1.9)

0 (0)

2 (2.2)

.58

Coronary artery dissection, n (%)

3 (2.8)

1 (7.1)

2 (2.2)

.29

Hemodynamic collapse, n (%)

2 (1.9)

0 (0)

2 (2.2)

.58

Respiratory arrest, n (%)

2 (1.9)

1 (7.1)

1 (1.1)

.11

Embolized
Microthrombi embolization, n (%)

12 (11.2)

4 (28.6)

8 (8.6)

.02

4 (30.8)

1 (25)

3 (37.5)

.71

Femoral embolization, n (%)

2 (15.4)

1 (25)

1 (12.5)

.77

Abdominal embolization, n (%)

1 (7.7)

0 (0)

1 (12.5)

.71

Iliac embolization, n (%)

1 (7.7)

0 (0)

1 (12.5)

.71

Brachial embolization, n (%)

1 (7.7)

0 (0)

1 (12.5)

.71

Periprocedural MI, n (%)

4 (30.8)

1 (25)

3 (37.5)

Stroke, n (%)

0 (0)

0 (0)

0 (0)

Death, n (%)

1 (0.9)

0 (0)

1 (1.1)

.69

93 (86.9)

12 (85.7)

81 (87.1)

.88

.71
*

Outcome
Successful intervention completed, n (%)
Abbreviation: MI, myocardial infarction.

5.9%, respectively. Coronary perforation occurred in 1.7% of cases,

was no difference in the incidence of retrieval failure, filter fracture,

while coronary dissection occurred in 2.5% of cases. The rates of

failure of crossing, or failure of deployment between SVG and native

death, stroke, and periprocedural MI were 0.8, 0.8, and 8.4%.

artery interventions. There was no difference in clinical outcomes
between the two groups (Table 2).

2.4

|

Vein grafts versus native coronary disease
3

|

DI SCU SSION

Coronary EPDs were primarily used in SVGs. Native artery interventions were more likely to be associated with failure to recapture the

Our study is the first to report the modes of failure of coronary EPDs

filter compared to SVG interventions (14.3 vs. 1.1%, p < .001). There

over a decade of use in the United States. The main findings of our

5
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study can be summarized as follows: (1) coronary EPDs were primarily

required in 10.9% of cases. EPD failure was associated with a low risk

utilized in SVG PCI (78%) but are also sometimes used in native artery

of death or stroke (<2%), vessel perforation or dissection (<5%), and

interventions; (2) the most common complication of coronary EPD

slow or no-reflow (<15%).

use was retrieval failure (49%) followed by filter fracture (28.6%),

Although prior studies have shown that routine use of EPDs in

which was in most cases managed by catheter-based retrieval or leav-

STEMIs of native coronary arteries does not improve outcomes,13

ing the filter in place, with emergency surgery needed in 10.9% of the

EPDs were used in native vessel PCI in 13% of the reports. In

cases.

our analysis, there was a significantly higher risk of failure to recapture

SVG PCI is associated with a high risk of MACE, primarily due to

the EPD in native vessel PCI (14.3 vs. 1.1%, p < .001). It might be rea-

the risk of distal embolization. Although PCI of the corresponding

sonable to use EPDs in selective cases of native vessel PCI during

native coronary is preferred to SVG PCI if feasible,10 SVG PCI is still

STEMI with massive thrombus burden and anticipation of no-reflow.

commonly performed. The SAFER trial demonstrated a significant

However, caution should be employed before their use, given slightly

benefit of EPD use in SVG PCI and formed the basis of current prac-

higher risk of recapture failure.

tice. Using an EPD in SVG PCI is recommended as class I in the US
PCI guidelines. In contrast, it was recently downgraded to IIA in the
European PCI guidelines based on data from observational stud-

3.1

|

Limitations

ies.11,12 The use of EPDs during SVG PCI has been shown to reduce
the risk of distal embolization and MACE.8 However, multiple studies

Our study is limited by selection bias resulting from the retrospective

have shown that EPD use during SVG PCI has been declining.11,12

analysis of the MAUDE and the selective optional reporting by

The decline in their use might indirectly lead to limited experience and

healthcare professionals. Second, the MAUDE database has several

higher complication rates.

shortcomings, including the submission of incomplete or unverified

EPDs carry a risk of complications, such as entrapment,11 leading

reports. Third, the incidence of each device's mode of failure cannot

to emergency cardiac surgery or death. Our study investigated the

be determined as the study lacks a denominator. Finally, a correlation

outcomes of the two currently available EPDs in the US: Spider FX

between the device failure and clinical adverse events cannot be

and Filterwire EZ. The Spider FX consists of a nitinol mesh filter with

accurately determined.

pore sizes ranging from 70 to 200 μm with a distal floppy tip. It can be
advanced after wiring the target lesion using any guidewire according
to the operator's preference. The Filterwire-EZ is a steerable

3.2

|

Conclusions

guidewire that is advanced across the target lesion, with a 110 μm
pore size filter bag. For most sizes, both filters have similar crossing

The most common modes of failure of coronary EPDs are failure of

profiles (3.2 French).

retrieval (49.6%) and filter fracture (28.6%). When using EPDs, careful

In our analysis, the most common mode of EPD failure was failure
to retrieve the filter, occurring in half of the reports. In >70% of the

attention to the technique is essential to avoid failures and subsequent complications.

cases, the filter was trapped against stent struts. While not specified
in the reviewed reports, buddy wires should never be used with EPDs,

CONFLIC T OF INT ER E ST

as inadvertent stent deployment over the buddy wire will lead to filter
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The second most common EPD failure mode was filter fracture
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